COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PXPX BHBH FPVFPV FLVFLV PVP-IPI CICI BLBL RDRD
Vitamin D study #75 of 89
2/23 Late treatment study
Lakkireddy et al., Research Square, doi:10.21203/rs.3.rs-152494/v1 (Preprint)
Impact of Pulse D Therapy on The Inflammatory Markers in Patients With COVID-19
Source   PDF   Share   Tweet
RCT 44 treatment and 43 control patients with vitamin D levels <30ng/ml, showing significant reduction in inflammatory markers with treatment of 60,000IU vitamin D per day for 8 days (10 days for BMI >25). Death and ICU admission was lower in the treatment group but not statistically significant.

Lakkireddy et al., 2/23/2021, Randomized Controlled Trial, India, South Asia, preprint, mean age 45.5, 9 authors, dosage 60,000IU days 1-8.
risk of death, 60.9% lower, RR 0.39, p = 0.27, treatment 2 of 44 (4.5%), control 5 of 43 (11.6%).
risk of ICU admission, 21.8% lower, RR 0.78, p = 0.74, treatment 4 of 44 (9.1%), control 5 of 43 (11.6%).
hospitalization time, 1.2% lower, relative time 0.99, p = 0.88, treatment 44, control 43.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 89 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
Submit